No registrations found.
ID
Source
Brief title
Health condition
Residual Neuromuscular Block
Sugammadex
Sponsors and support
Intervention
Outcome measures
Primary outcome
Time to complete recovery of neuromuscular function after sugammadex administration.
Secondary outcome
None
Background summary
The sugammadex dose required to achieve a TOF-ratio of 1 is not known when monitoring is not used. Administration of sugammadex based on the rocuronium dosage, while aiming for complete recovery, should reduce the risk of residual NMB.
Study objective
The sugammadex dose required to achieve a TOF-ratio of 1 is not known when monitoring is not used. Administration of sugammadex based on the rocuronium dosage, while aiming for complete recovery, should reduce the risk of residual NMB.
Study design
N.A.
Intervention
None
Inclusion criteria
->18 years
-American Society of Anesthesiologists physical status I-III
-Scheduled to undergo general anesthesia with the use of a neuromuscular blocking agent for elective surgery
Exclusion criteria
-Neuromuscular disease
-Diabetes mellitus
-Obesity defined as a BMI >30
-Indication for a rapid sequence induction, -Expected difficult intubation or ventilation -Chronic kidney failure (EGFR <30), liver failure, pregnancy and allergy to neuromuscular blocking agent (rocuronium) or to the reversal agent (sugammadex).
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL7472 |
| NTR-old | NTR7714 |
| Other | METC LUMC : G18.004 |